Pre-market JPX 25 Feb 2026: 9164.T TRYT Inc. at JPY 875, oversold bounce setup

TRYT Inc. (9164.T) trades at JPY 875.00 in the JPX pre-market on 25 Feb 2026, setting up a possible short-term oversold bounce. The stock shows narrow intraday range (day low JPY 872.00, day high JPY 876.00) and below-average volume at 288,800 shares versus avg 606,043. For traders watching mean reversion, this compressing price near the Keltner middle of JPY 875.00 suggests a measured bounce trade, while fundamental metrics require careful risk controls.

Market snapshot and trading context for 9164.T stock

TRYT Inc. (9164.T) is listed on JPX and operates in Japan’s staffing and healthcare staffing sector. Market cap is JPY 87,500,000,000 with EPS 21.61 and PE 40.49. Volume is light at 288,800, giving a relative volume of 0.48, which raises caution on execution and slippage for larger orders.

Technical setup for 9164.T stock: oversold bounce criteria

Price sits at the Keltner channel middle (KC middle JPY 875.00) with upper and lower bounds at JPY 880.00 and JPY 870.00. ADX reads 25.00, showing trend strength is modest and favouring a range bounce. ATR is JPY 2.50, so a disciplined stop under JPY 870.00 limits risk to about JPY 5.00. Low volume and tight range make a short-term mean-reversion trade viable if momentum returns.

Fundamentals and valuation: why fundamentals matter

TRYT’s price-to-book ratio is 2.90 and price-to-sales is 1.50, which sits above some Industrials peers. Debt-to-equity is 1.20, and current ratio is 0.78, signalling tighter near-term liquidity. Return on equity is 7.69% and free cash flow per share is JPY 39.73, showing cash generation but mixed leverage and liquidity.

Trade plan and price targets for an oversold bounce

A conservative bounce entry near JPY 873.00–875.00 targets a first take-profit at JPY 920.00 (about 5.14% upside). A stretch target is JPY 1,050.00 for traders holding through momentum shift. Place a stop-loss below JPY 870.00. Use position sizing to limit portfolio risk given average volume of 606,043 shares.

Meyka AI rates 9164.T with a score out of 100 and forecast

Meyka AI rates 9164.T with a score out of 100: 75.97 / 100 (Grade B+, Suggestion: BUY). This grade factors S&P 500 comparison, sector and industry peers, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects a one-year figure of JPY 373.55, implying -57.31% vs current JPY 875.00. Forecasts are model-based projections and not guarantees.

Risks and catalysts to watch in pre-market trading

Key risks include low current ratio (0.78), elevated debt-to-equity (1.20), and thin pre-market liquidity. Catalysts that could trigger a stronger bounce include better-than-expected staffing demand updates, urgent medical staffing contracts, or sector strength in Industrials. For broader market tone and fund flows, see recent market reports on institutional activity MarketBeat report and sector moves Nasdaq recap.

Final Thoughts

Short-term traders should view 9164.T stock at JPY 875.00 as a measured oversold-bounce setup in the pre-market on 25 Feb 2026. Technicals show tight range compression around the Keltner middle and modest trend strength, which supports a mean-reversion entry with a stop below JPY 870.00 and an initial target near JPY 920.00. Fundamentals are mixed: PE 40.49 and PB 2.90 indicate a premium versus some peers, while debt and current ratio require caution. Meyka AI’s forecast model projects JPY 373.55 one-year, implying -57.31% relative to today; this highlights divergence between short-term technical trade ideas and longer-term model projections. Forecasts are model-based projections and not guarantees. Use tight risk controls and check intraday volume on JPX before entering. For more detailed live quotes see the TRYT stock page on Meyka AI for real-time indicators and order-flow signals.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.